US EditionPublished • loading... • Updated
Alzheimer's Benefits May Continue After Donanemab Treatment Ends, Data Suggest
Summary by MedPage Today
2 Articles
2 Articles
MedPage TodayReposted by 
Anti-Aging, Acupuncture and Health News
Anti-Aging, Acupuncture and Health NewsAlzheimer's Benefits May Continue After Donanemab Treatment Ends, Data Suggest
(MedPage Today) -- New data suggested that donanemab (Kisunla) sustained long-term benefits after a limited dosing period in a subgroup of people with early symptomatic Alzheimer's disease. Early Alzheimer's patients who completed their course...
·New York, United States
Read Full ArticleCoverage Details
Total News Sources2
Leaning Left0Leaning Right0Center1Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
